Hermes Mendoza-Zavala, APRN
Psychiatric/Mental Health · McAllen, TXNPI 1164964805
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,317 of the $12,386 with a category attached, or 75.2%. 17 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 27.3% of the total. 2025 is the largest year on record at $6,614, more than ten times the $166 reported in 2022. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $32.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$836
- Ironshore Pharmaceuticals Inc.$608
- plus $4K from 11 others
What the payments were for
- Speaking & faculty fees$2,80323%
- Food & beverage$9,31775%
- Education$2662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $3,376 |
| Teva Pharmaceuticals USA, Inc. | 53 | $1,695 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $1,084 |
| Alkermes, Inc. | 41 | $1,032 |
| Neurocrine Biosciences, Inc. | 41 | $836 |
| Ironshore Pharmaceuticals Inc. | 26 | $608 |
| AbbVie | 31 | $579 |
| Lundbeck LLC | 28 | $553 |
| Vanda Pharmaceuticals Inc. | 11 | $504 |
| Corium, LLC | 25 | $503 |
| Axsome Therapeutics, Inc. | 16 | $489 |
| Collegium Pharmaceutical, Inc. | 13 | $340 |
| Supernus Pharmaceuticals, Inc. | 15 | $271 |
| E.r. Squibb & Sons, L.L.C. | 4 | $193 |
| Idorsia Pharmaceuticals US Inc | 14 | $166 |
| Johnson & Johnson | 4 | $95 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$2,928
- LYBALVI$1,477
- CAPLYTA$502
- Fanapt$257
- INGREZZA$253
- Auvelity$250
- VRAYLAR$239
- Austedo XR$217
- COBENFY$135
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- AUSTEDO$124
- UZEDY$124
- JORNAY PM$103
How this compares
$12,386 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 19 | $158,013 |
| IngrezzaValbenazine Tosylate | 13 | $99,626 |
| RexultiBrexpiprazole | 66 | $95,489 |
| Invega SustennaPaliperidone Palmitate | 33 | $69,494 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $42,984 |
| CaplytaLumateperone Tosylate | 23 | $36,908 |
| VraylarCariprazine Hcl | 15 | $19,966 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,137 |
| Chlorpromazine Hcl | 12 | $3,472 |
| Trazodone Hcl | 281 | $3,401 |
| Divalproex Sodium ErDivalproex Sodium | 47 | $2,868 |
| Quetiapine Fumarate | 134 | $2,632 |
| Mirtazapine | 92 | $2,260 |
| Atomoxetine Hcl | 13 | $2,091 |
| Olanzapine | 80 | $1,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,695 | $158,01319 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $836 | $99,62613 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $3,376 | $95,48966 claims |
| Johnson & JohnsonInvega Sustenna | $95 | $69,49433 claims |
| Alkermes, Inc.Lybalvi | $1,032 | $42,98421 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,084 | $36,90823 claims |
| AbbVieVraylar | $579 | $19,96615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in McAllen
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.